Compare Cytokinetics Inc (CYTK) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.63B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Cytokinetics Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | NVDW | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $87.26 | $52.59 |
52-Week Low | $34.31 | $31.88 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $76.24, down 1.61% over 24 hours, with a bearish technical signal from moving averages and neutral oscillators. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, while revenue reached $88.04 million in 2025. Despite negative profitability margins, strong analyst sentiment exists with 34 buy ratings and a consensus price target of $111.14, driven by optimism around Myqorzo's commercial uptake and recent UK regulatory approval.
The outlook hinges on Myqorzo's commercial execution and pipeline expansion, offering significant upside if revenue growth accelerates. Key risks include persistent cash burn, high debt-to-asset ratio of 81.23%, and competitive pressures in the cardiovascular drug market. Investors should weigh the high valuation (P/S of 140.65) against the potential for future profitability breakthroughs.
NVDW, trading at $38.53, gained 3.21% in the last session with a bullish technical signal driven by moving averages. The stock exhibits strong weekly dividend activity, with recent payouts ranging from $0.13 to $0.48, indicating a focus on income generation. Key resistance lies near $39, while support is established around $36–37.
The outlook hinges on NVDW's ability to sustain its dividend strategy amid market volatility. Risks include payout consistency and reliance on underlying asset performance. Opportunities exist for income-focused investors, but cautious monitoring of technical overbought signals is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
